
Last updated: 3 months ago
Tiziana Life Sciences 6-K Report: Pioneering Long COVID Treatment Insights
Tiziana Life Sciences' 6-K reveals progress on nasal anti-CD3 foralumab, targeting long COVID. Key insights on innovative treatment and market potential included.